Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 10;14:746. doi: 10.1038/s41467-023-36334-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Kaplan–Meier plot displays tumor initiation overtime in nude mice injected subcutaneously with 15,000 HT29-M6 cells alone (gray; n = 24), co-injected with 50,000 CCD-18Co non-treated (blue; n = 50) or pre-treated with oxaliplatin (red; n = 44). **p = 0.0015, ***p = 0.0002. Drawing modified from Calon et al.³³. b Quantitative analysis of oxaliplatin-treated HT29-M6 cells cultured with conditioned media (CM) from CCD-18Co non-treated or pre-treated with oxaliplatin. n = 3 biologically independent experiments. Values are mean ± sd. p value is indicated. c Kaplan–Meier curve displays DFS for GSE17536 patients (n = 177) presenting low (blue; n = 112) or high expression levels of aFib-RS (red; n = 65). HR, CI, p value are indicated. d Kaplan–Meier curve displays DFS for GSE39582 patients (n = 519) presenting low (blue; n = 332) or high expression levels of aFib-RS (red; n = 187). HR, CI, p value are indicated. e aFib-RS levels in n = 1029 CRC patients classified by CMS subtypes (CMS1 n = 175; CMS2 n = 445; CMS3 n = 147, CMS4 n = 262). Central mark indicates the median, box extends from the 25th to 75th percentiles, whiskers represent the maximum and minimum data point. p values are indicated. f Kaplan–Meier curve displays DFS for GSE39582_CMS4 patients (n = 121) presenting low (blue; n = 81) or high expression levels of aFib-RS (red; n = 40). HR, CI, p value are indicated. g GSEA of aFib-RS in the GSE72970 subset of tumor samples collected before treatment comparing patients responding to CT (n = 20) and unresponsive (n = 12) patients. h GSEA of aFib-RS in the GSE14333 subset of tumor samples collected before treatment comparing relapsing (n = 13) to non-relapsing (n = 38) patients after CT. ES enrichment score, NES normalized enrichment score, FDR false discovery rate. TFS tumor-free survival, CRC colorectal cell line (HT29-M6). Fib fibroblasts (CCD-18Co), DFS disease-free survival, HR hazard ratio, CI confidence interval, Ox oxaliplatin, GSEA gene set enrichment analysis, RLU relative luminescence unit. Two-sided, unpaired t-test p values (p) are indicated for b, e. Log-rank (Mantel–Cox test) p values (p) are indicated for a, c, d, f. GSEA nominal p value (p) and FDR-adjusted p value are indicated for g, h. Source data are provided as a Source Data file.